Study of ASTX029 in Subjects With Advanced Solid Tumors

Phase 1

Active, not recruiting

• Conditions: Solid Tumor, Adult
• Interventions: Drug: ASTX029

• Registration Number: NCT03520075
• Lead Sponsor: Taiho Oncology, Inc.

Brief Summary

This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to subjects with advanced solid malignancies who are not candidates for approved or available therapies.

Detailed Description

ASTX029 is a synthetic small molecule inhibitor of extracellular signal-regulated kinases (ERKs) 1/2. ASTX029 has not been previously evaluated in human subjects. The Phase 1 portion of this study will assess safety and determine the maximum tolerated dose, the recommended Phase 2 dose (RP2D), and the recommended dosing regimen of ASTX029 administered orally. The Phase 2 portion will assess preliminary clinical activity in tumors characterized by gene aberrations in the mitogen-activated protein kinase (MAPK) signal pathway that may confer sensitivity to ASTX029.

Study Timeline

• Study First Submitted: 2018-04-18
• Study First Submitted QC: 2018-05-08
• Study First Posted: 2018-05-09
• Study Start: 2018-05-10
• Primary Completion: 2024-08-01
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-05
• Last Update Posted: 2025-01-07
• Study Completion: 2025-12-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Subjects must fulfill all of the following inclusion criteria.

1. Able to understand and comply with study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.

2. Men or women 18 years of age or older.

3. Subjects with histologically or cytologically confirmed advanced solid tumors that are metastatic or unresectable, who are refractory or have relapsed after treatment with available therapies or for whom standard life-prolonging measures or approved therapies are not available. In Phase 1 Part B and in the Phase 2 portion of the protocol, subjects must also have documented gene alterations in the MAPK pathway as detailed in the protocol.

4. In Phase 1 Part B of the protocol, subjects must have disease lesions that are amenable to biopsy.

5. In the Phase 2 portion of the protocol, subjects must have measurable disease according to RECIST v1.1.

6. Eastern Cooperative Oncology Group performance status 0 to 2.

7. Acceptable organ function as evidenced by the following laboratory data:

   1. Aspartate aminotransferase (AST) and alanine aminotransferase ≤2×upper limit of normal (ULN) or ≤3 ULN in the presence of liver metastases.
   2. Total serum bilirubin ≤1.5×ULN.
   3. Absolute neutrophil count (ANC) ≥1500 cells/mm3.
   4. Platelet count ≥100,000 cells/mm3.
   5. Calculated creatinine clearance (by the standard Cockcroft Gault formula) of ≥50 mL/min or glomerular filtration rate of ≥50 mL/min.

8. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]; see protocol for details) must not be pregnant or breastfeeding and must have a negative pregnancy test within 24 hours before the first dose of study treatment. While receiving study treatment and for at least 5 half-lives of ASTX029 or metabolite plus 30 days after completing treatment, women of child-bearing potential must agree to practice highly effective contraceptive measures (as described in the protocol) and must refrain from donating eggs (ova, oocytes) for the purpose of reproduction.

9. Men with female partners of child-bearing potential (according to recommendations of the CTFG; see protocol for details) must agree to, during the treatment period and for at least 5 half-lives of ASTX029 or metabolite plus 90 days after completing treatment, practice highly effective contraceptive measures (as described in the protocol), not to father a child, and to refrain from donating sperm.

Exclusion Criteria

1. Hypersensitivity to ASTX029 or excipients of the drug product.

2. Poor medical risk in the investigator's opinion because of systemic diseases in addition to the cancer under study, for example, uncontrolled infections.

3. Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of study outcomes or interfere with the absorption or metabolism of ASTX029.

4. Prior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX029), as follows:

   1. Cytotoxic chemotherapy or radiotherapy within 3 weeks prior. Palliative radiotherapy to a single lesion within 2 weeks prior. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to ≤Grade 1.
   2. Monoclonal antibodies within 4 weeks prior. Any encountered treatment-related toxicities not stabilized or resolved to ≤Grade 1.
   3. Molecularly targeted drug or investigational drugs, without the potential for delayed toxicity, within 4 weeks of the first dose of study treatment or 5 half-lives (minimum 14 days), whichever is shorter. Any encountered treatment-related toxicities (excepting alopecia) not stabilized or resolved to ≤Grade 1.

5. Prior treatment with extracellular signal-regulated kinase (ERK) inhibitors.

6. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the following conditions:

   1. Abnormal left ventricular ejection fraction (LVEF; <50%) on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
   2. Congestive cardiac failure of ≥Grade 3 severity according to New York Heart Association functional classification defined as patients with marked limitation of activity and who are comfortable only at rest.
   3. Unstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
   4. History or evidence of long QT interval corrected for heart rate (QTc), ventricular arrhythmias including ventricular bigeminy, complete left bundle branch block, clinically significant bradyarrhythmias such as sick sinus syndrome, second- and third-degree atrioventricular (AV) block, presence of cardiac pacemaker or defibrillator, or other significant arrhythmias.
   5. Screening 12-lead electrocardiogram (ECG) with measurable QTc interval of ≥470 msec. (Fridericia's formula should be used to calculate the QTc interval throughout the study.)

7. Known history of human immunodeficiency virus (HIV) infection or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.

8. Known brain metastases, unless previously treated and stable for at least 3 months with or without steroids.

9. Known significant mental illness or other conditions, such as active alcohol or other substance abuse that, in the opinion of the investigator, predispose the subject to high risk of noncompliance with the protocol treatment or assessments.

10. History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) including:

    1. Presence of predisposing factors to RVO or CSR (eg, uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus) or

    2. Visible retinal pathology as assessed by ophthalmic examination at screening that is considered a risk factor for RVO or CSR such as:

       • Evidence of optic disc cupping or
       • Evidence of new visual field defects on automated perimetry or
       • Intraocular pressure >21 mmHg as measured by tonography.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Phase 1 Regimen 1	ASTX029	Dose escalation and expansion: Regimen 1: ASTX029 orally once a day for 21 days of each 21-day cycle.
Phase 1 Regimen 2	ASTX029	Dose escalation and expansion: Regimen 2: ASTX029 orally once a day for 14 days of each 21-day cycle.
Phase 2	ASTX029	ASTX029 at the RP2D of the selected dosing regimen identified in Phase 1 to subjects with tumors characterized by gene aberrations in the MAPK signal pathway that may confer sensitivity to ASTX029.

Primary Outcome Measures

Name	Time	Method
Safety (Phase 1) - Dose-limiting toxicities including incidence of Treatment-Emergent Adverse Events	End of each dosing cycle (Day 21 of 21-day cycle)	Number of subjects with dose-limiting toxicities
Efficacy (Phase 2) - Response Evaluation Criteria in Solid Tumors using RECIST v1.1	Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year	Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic profile of ASTX029 - Cmax	Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2	2) Maximum plasma concentration
Pharmacokinetic profile of ASTX029 - AUC	Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2	1) Area under the time-concentration curve
Pharmacokinetic profile of ASTX029 - Half-life	Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2	5) Elimination half-life
Pharmacokinetic profile of ASTX029 - Metabolites	Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2	6) Analysis of ASTX029 metabolites if applicable
Efficacy - DOR	Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year	Duration of response
Efficacy - DCR	Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year	Disease control rate
Efficacy - PFS	Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year	Progressive-free survival
Efficacy - OS	Baseline to measured progressive disease or start of new anticancer therapy, through study completion, an average of 6 months to 1 year	Overall survival
Pharmacokinetic profile of ASTX029 - Cmin	Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2	3) Minimum plasma concentration
Pharmacokinetic profile of ASTX029 - Tmax	Day 1 and 2 of Cycle 1 and Cycle 2 for Regimen 1, and Day 1, 2, 14, and 15 of Cycle 1 for Regimen 2	4) Time to reach maximum concentration
Target engagement in tumor tissues - pRSK	Day 8 of Cycle 2	Inhibition of phosphorylated ribosomal s6 kinase protein in response to ASTX029 treatment in fresh tumor biopsies

Trial Locations

Locations (31)

Cambridge University Hospitals NHS Foundation Trust; 🇬🇧 Cambridge, United Kingdom

City of Hope Comprehensive Cancer Center; 🇺🇸 Duarte, California, United States

University of Southern California Norris Comprehensive Cancer Center Site#114; 🇺🇸 Los Angeles, California, United States

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Site# 107; 🇺🇸 Los Angeles, California, United States

Institut Català d'Oncologia Badalona Site#240; 🇪🇸 Barcelona, Spain

Hospital Universitari Vall d'Hebrón Servicio de Oncología, Sala coordinación UITM Site#243; 🇪🇸 Barcelona, Spain

Hoag Memorial Hospital Site#115; 🇺🇸 Newport Beach, California, United States

University of California Davis Medical Center Site #121; 🇺🇸 Sacramento, California, United States

California Pacific Medical Center - Sutter Pacific Medical Center Site#117; 🇺🇸 San Francisco, California, United States

Smilow Cancer Hospital at Yale New Haven Site#105; 🇺🇸 New Haven, Connecticut, United States

Holden Comprehensive Cancer Center; 🇺🇸 Iowa City, Iowa, United States

The Sidney Kimmel Comprehensive Cancer Center Site#106; 🇺🇸 Baltimore, Maryland, United States

Massachusetts General Hospital Site#103; 🇺🇸 Boston, Massachusetts, United States

Dana Farber Cancer Institute Site#104; 🇺🇸 Boston, Massachusetts, United States

University of Michigan Rogel Cancer Center Site #113; 🇺🇸 Ann Arbor, Michigan, United States

Columbia University Irving Medical Center - Herbert Irving Pavilion Site#112; 🇺🇸 New York, New York, United States

Providence Portland Medical Center Site #118; 🇺🇸 Portland, Oregon, United States

Oregon Health and Science University Site #122; 🇺🇸 Portland, Oregon, United States

University of Pennsylvania-Abramson Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States

The University of Texas MD Anderson Cancer Center Site#111; 🇺🇸 Houston, Texas, United States

START - South Texas Accelerated Research Therapeutics, LLC Site# 101; 🇺🇸 San Antonio, Texas, United States

Virginia Cancer Specialists Site#102; 🇺🇸 Fairfax, Virginia, United States

Centre Léon Bérard Service d'Oncologie Médicale Site#202; 🇫🇷 Lyon, Rhone-Alpes, France

Hôpital de la Timone Site #201; 🇫🇷 Marseille, France

Hospital Universitari Germans Trias i Pujol; 🇪🇸 Barcelona, Spain

Hospital Universitario Dexeus Site#241; 🇪🇸 Barcelona, Spain

Clinica Universidad de Navarra Madrid Site #242; 🇪🇸 Madrid, Spain

Clínica Universidad de Navarra Site#242; 🇪🇸 Madrid, Spain

The Christie NHS Foundation Trust Site#220; 🇬🇧 Manchester, England, United Kingdom

The Newcastle Upon Tyne Hospitals NHS Foundation Trust Site #221; 🇬🇧 Newcastle Upon Tyne, United Kingdom

Churchill Hospital Site #224; 🇬🇧 Oxford, United Kingdom